日本の膵がん治療市場：がんタイプ別、治療タイプ別、エンドユーザー別、地域別、機会、予測、2019年～2033年

日本の膵がん治療の市場規模は、2026年～2033年の予測期間中に12.61％のCAGRで拡大し、2025年の1億2,520万米ドルから2033年には3億2,377万米ドルに成長すると予測されています。ヘルスケア技術の急速な進歩、高齢化人口の拡大、同国における膵臓がんの有病率の上昇が市場促進要因のひとつです。国内の主要製薬企業は、慢性疾患の負担増に対処するため、新規治療法の開発・導入にますます注力しています。世界がん研究基金の推計によると、日本では2022年に4万7,627人の膵臓がん患者が新たに報告されました。

製薬会社と研究機関の協力関係の強化が、免疫療法や遺伝子療法を含む治療法の革新を促進しています。さらに、日本には高度に洗練されたヘルスケア施設があるため、患者集団に質の高い医療を提供することができます。一方、医療インフラを強化し、がん研究への資金提供を後押しする政府の取り組みは、市場の成長と拡大をさらに後押ししています。こうした取り組みにより、先進的な治療法やがんの早期発見技術へのアクセスが向上し、医療関係者が膵臓がんの攻撃的な性質に対処できるようになっているからです。

当レポートでは、日本の膵がん治療市場について調査し、市場の概要とともに、がんタイプ別、治療タイプ別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。

目次

第1章 プロジェクトの範囲と定義

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 日本膵がん治療市場の見通し（2019年～2033年）

• 市場規模分析と予測
• 市場シェア分析と予測
• 2025年市場マップ分析
  • がんタイプ別
  • 治療タイプ別
  • エンドユーザー別
  • 地域別

第5章 需要供給分析

第6章 バリューチェーン分析

第7章 ポーターのファイブフォース分析

第8章 PESTLE分析

第9章 価格分析

第10章 市場力学

• 市場の促進要因
• 市場の課題

第11章 市場動向と発展

第12章 規制状況

第13章 臨床試験

第14章 ケーススタディ

第15章 競合情勢

• 市場リーダートップ5の競合マトリックス
• 参入企業トップ5のSWOT分析
• 市場の主要企業トップ10の情勢
  • AstraZeneca K.K.
  • Pfizer Japan Inc.
  • Teva Takeda Yakuhin Ltd.
  • Novartis Pharma K.K.
  • Sanofi K.K.
  • GlaxoSmithKline K.K.
  • Merck & Co., Inc.
  • Bristol-Myers Squibb K.K.
  • Eli Lilly Japan K.K.
  • Eisai Co., Ltd.

第16章 戦略的提言

第17章 調査会社について・免責事項

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. Japan Pancreatic Cancer Treatment Market, By Value, In USD Million, FY2019-FY2033F
• Figure 2. Japan Pancreatic Cancer Treatment Market Share (%), By Cancer Type, FY2019-FY2033F
• Figure 3. Japan Pancreatic Cancer Treatment Market Share (%), By Treatment Type, FY2019-FY2033F
• Figure 4. Japan Pancreatic Cancer Treatment Market Share (%), By End-user, FY2019-FY2033F
• Figure 5. Japan Pancreatic Cancer Treatment Market Share (%), By Region, FY2019-FY2033F
• Figure 6. By Cancer Type Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 7. By Treatment Type Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 8. By End-user Map-Market Size (USD Million) & Growth Rate (%), FY2025
• Figure 9. By Region Map-Market Size (USD Million) & Growth Rate (%), FY2025

Japan pancreatic cancer treatment market is projected to witness a CAGR of 12.61% during the forecast period FY2026-FY2033, growing from USD 125.20 million in FY2025 to USD 323.77 million in FY2033. The rapid advancements in healthcare technologies, expansion of the aging population, and increasing prevalence of pancreatic cancer in the country are some of the drivers of the market. Leading pharmaceutical companies in the country are increasingly focusing on developing and introducing novel therapies to combat the increasing burden of the chronic condition. According to the estimates of the World Cancer Research Fund, 47,627 new cases of pancreatic cancer were reported in Japan in 2022.

Increasing collaborations between pharmaceutical companies and research institutions are fostering innovation in treatment modalities, including immunotherapy and gene therapy. Additionally, the availability of highly sophisticated healthcare facilities in the country ensures the provision of high-quality care for the patient population. Meanwhile, government initiatives to enhance healthcare infrastructure and boost funding for cancer research are further supporting the market's growth and expansion as these efforts improve access to advanced therapies and early cancer detection technologies, allowing the medical professionals to address the aggressive nature of pancreatic cancer.

Increasing Research Activities Support Market Expansion

Rising research efforts that focus on developing novel therapies such as targeted agents, immunotherapies, and gene therapies are providing lucrative growth opportunities for the market. Japanese research institutions are collaborating with other research institutions across the globe to develop new therapies that aid in combating the growing threat of pancreatic cancer. For instance, recently Israeli and Japanese researchers have made a significant breakthrough in cancer treatment by developing a highly targeted inhibitor for the Matrix Metallopeptidase 7 (MMP7) enzyme. This enzyme plays a critical role in cancer growth and spread, particularly in aggressive forms like pancreatic cancer. The collaborative effort involved the University of Tokyo and the Hebrew University of Jerusalem, the Weizmann Institute of Science. Such collaborative activities are expected to bolster the availability of novel therapeutic solutions for pancreatic cancer and provide lucrative growth opportunities for the market.

Technological Innovations in Testing Methods Boost Market Growth

Technological innovations in testing methods are positively influencing the market's expansion by enabling personalized care and early disease detection. Such innovations also enhance treatment outcomes by facilitating timely interventions, which are crucial for managing pancreatic cancer's aggressive nature. Early detection also supports the use of targeted therapies and precision medicine, optimizing treatment efficacy and minimizing side effects. Thus, leading research institutions across the country are focusing on developing new methods for testing pancreatic cancer. For instance, in February 2025, researchers from Osaka University announced that they have developed a method for testing pancreatic cancer with DNA collected during gastric examinations from a modified catheter. This technique streamlines the early detection of pancreatic cancer, which is usually challenging, by employing modified catheters for gathering samples. The technique also improves early diagnosis rates by analyzing pancreatic juice flowing into duodenum.

Additionally, in September 2024, researchers from Kyoto University announced that the university along with Arkray Inc. have developed an innovative artificial intelligence-based method to detect early-stage pancreatic cancer. The team utilized microRNAs, small RNA fragments that regulate genetic functions, alongside conventional tumor markers to create a diagnostic model. Such breakthroughs could significantly improve rate of detection, providing better survival outcomes for the patients and propel the market's demand.

Exocrine Cancer Accounts for Significant Share of the Market

Due to the high prevalence and aggressive nature, exocrine pancreatic cancer dominates the market. This cancer is highly invasive and is diagnosed at later stages due to lack of availability of effective screening tools and early symptoms. Additionally, the expansion of the aging population in the country further increases the prevalence of the condition. As per the estimates of the World Economic Forum, more than 1 in 10 people are 80 or older in Japan.

Meanwhile, evolving lifestyle is also increasing the prevalence of exocrine pancreatic cancer in Japan. Rising popularity of smoking and consumption of animal fat in the country are significantly contributing to the growing cases. In order to combat the growing threat of the condition, major pharma corporations and research institutions are focusing on developing innovative therapies, improving survival rates and driving the growth of the market.

Hospitals Hold Major Market Share

Due to the central role hospitals play in providing comprehensive care for complex diseases and disorders such as cancer, they hold a significant share in the market. Hospitals are the primary sites in Japan for administration of radiation therapy and chemotherapy and for performing surgeries, essential for treating pancreatic cancer. Hospitals such as Cancer Institute Hospital of JFCR in Tokyo are leading sites for treating pancreatic cancer as they adopt advanced therapies such as immunotherapies and targeted treatment solutions. Meanwhile, government backed initiatives and investments in infrastructure of hospitals in Japan to ensure the provision of high-quality care for the patient population are also making hospitals the preferred setting for management of pancreatic cancer.

Future Market Scenario (FY2026 - FY2033F)

The market is expected to witness significant growth over the forecast period due to increasing innovations in immunotherapy, precision medicine, and targeted therapies. Meanwhile, growing focus on expansion of early pancreatic cancer detection technologies with the help of novel diagnostic techniques and artificial intelligence powered cancer detection tools are further expected to bolster the market's demand in Japan.

With major pharmaceutical companies in Japan investing heavily in next-generation cancer treatments, the number of treatment solutions available for the patient population are expected to increase significantly in the coming years. As the country's regulatory framework evolves and more cost-effective treatments emerge, the quality of life of the patients will improve along with the survival rates.

Key Players Landscape and Outlook

Startups across Japan are supporting the development of new tools that harness artificial intelligence for treating and diagnosing pancreatic cancer among other diseases. Companies are focusing on high-intensity focused ultrasound (HIFU) as the HIFU waves do not damage heathy cells they pass through and can be focused on a small region inside the body. Meanwhile, conventional radiotherapy damages both healthy cells and cancer cells that the radiation passes through. Thus, clinicians in the country are now working on ensuring that HIFU becomes the standard treatment for pancreatic cancer.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Japan Pancreatic Cancer Treatment Market Outlook, FY2019-FY2033F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Cancer Type
    • 4.2.1.1. Endocrine Pancreatic Cancer
    • 4.2.1.2. Exocrine Pancreatic Cancer
  • 4.2.2. By Treatment Type
    • 4.2.2.1. Chemotherapy
    • 4.2.2.2. Radiation Therapy
    • 4.2.2.3. Targeted Therapy
    • 4.2.2.4. Immunotherapy
    • 4.2.2.5. Hormone Therapy
    • 4.2.2.6. Others
  • 4.2.3. By End-user
    • 4.2.3.1. Hospitals
    • 4.2.3.2. Clinics
    • 4.2.3.3. Cancer Care Centers
    • 4.2.3.4. Others
  • 4.2.4. By Region
    • 4.2.4.1. North [Hokkaido and Tohoku]
    • 4.2.4.2. Central [Kanto and Chubu]
    • 4.2.4.3. South [Kansai, Chugoku, Shikoku, and Kyushu & Okinawa]
  • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, FY2025)
• 4.3. Market Map Analysis, FY2025
  • 4.3.1. By Cancer Type
  • 4.3.2. By Treatment Type
  • 4.3.3. By End-user
  • 4.3.4. By Region

5. Demand Supply Analysis

6. Value Chain Analysis

7. Porter's Five Forces Analysis

8. PESTLE Analysis

9. Pricing Analysis

10. Market Dynamics

• 10.1. Market Drivers
• 10.2. Market Challenges

11. Market Trends and Developments

12. Regulatory Landscape

13. Clinical Trials

14. Case Studies

15. Competitive Landscape

• 15.1. Competition Matrix of Top 5 Market Leaders
• 15.2. SWOT Analysis for Top 5 Players
• 15.3. Key Players Landscape for Top 10 Market Players
  • 15.3.1. AstraZeneca K.K.
    • 15.3.1.1. Company Details
    • 15.3.1.2. Key Management Personnel
    • 15.3.1.3. Products and Services
    • 15.3.1.4. Financials (As Reported)
    • 15.3.1.5. Key Market Focus and Geographical Presence
    • 15.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 15.3.2. Pfizer Japan Inc.
  • 15.3.3. Teva Takeda Yakuhin Ltd.
  • 15.3.4. Novartis Pharma K.K.
  • 15.3.5. Sanofi K.K.
  • 15.3.6. GlaxoSmithKline K.K.
  • 15.3.7. Merck & Co., Inc.
  • 15.3.8. Bristol-Myers Squibb K.K.
  • 15.3.9. Eli Lilly Japan K.K.
  • 15.3.10. Eisai Co., Ltd.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

16. Strategic Recommendations

17. About Us and Disclaimer